Last updated: February 27, 2026
What is NDC 46122-0783?
NDC 46122-0783 identifies [Drug Name], a drug approved for [indication]. It is manufactured by [manufacturer] and approved by the FDA in [approval year]. The drug is administered via [administration route] and is available in [dosage form and strengths].
Market Size and Demand
Current Market Landscape
- Market penetration: The drug is indicated for [specific patient demographic], with an estimated [number] of eligible patients in the U.S.
- Market competitors: The key competitors include [list primary alternatives, e.g., other branded drugs, biosimilars, or generics].
- Market growth rate: The overall market for this therapeutic class is projected to grow at [percentage]% CAGR over the next [number] years, driven by [factors: increasing prevalence, new indications, improved diagnostics].
Usage Trends
- Prescription volume: Over the past [period], prescriptions for this drug increased by [percentage]%, largely driven by [specific factors, e.g., expanded indications, formulary inclusion].
- Adoption barriers: Key barriers include [cost concerns, regulatory hurdles, competition from biosimilars].
Pricing Analysis
Current Price Point
- List price per unit (e.g., per injection, tablet, or vial): $[amount]
- Average wholesale price (AWP): $[amount]
- Actual transaction price range: $[amount] to $[amount]
- Pricing varies based on [dosage, supply chain agreements, insurance coverage].
Comparative Pricing
| Product |
List Price |
AWP |
Indications |
Market Share |
| [Brand A] |
$[amount] |
$[amount] |
[Indication] |
[Percentage]% |
| [Brand B] |
$[amount] |
$[amount] |
[Indication] |
[Percentage]% |
Price Trends
- Prices have [increased/decreased] by [percentage]% over [timeframe], influenced by [patent expirations, biosimilar entries, new indications].
- Upcoming market entries or patent expirations could impact prices by [projection]% over the next [timeframe].
Future Price Projections
Factors Influencing Price
- Patent status: The patent expiration is scheduled for [date], opening the market to biosimilars or generics, potentially reducing prices by [estimated]%.
- Market competition: Entry of biosimilars could lead to a [percentage]% decrease in list prices.
- Regulatory changes: Price negotiations or reimbursement policies by CMS and private insurers could influence net prices.
Forecast Scenarios
| Scenario |
Price Adjustment |
Timeline |
Assumptions |
| Base Case |
Stable prices with minor fluctuations |
Next 3 years |
No major patent filings or biosimilar entries |
| Best Case |
Price reduction by 20% |
1-2 years |
Biosimilar approval and market penetration |
| Worst Case |
Price increase of 10% |
Next 2 years |
Increased demand and limited supply |
Estimated Average Price Range (Next 3 Years)
$[range] to $[range]
Strategic Considerations
- The patent cliff is approaching in [year], prompting early entry strategies for biosimilars.
- Insurance coverage and formulary placement impact net prices and market share.
- Clinical trial data and label expansions could influence pricing flexibility.
Key Takeaways
- The drug's current market price is $[amount], with growing demand driven by expanding indications.
- Competitive pressures from biosimilars and generics are expected to lower prices starting [year].
- Price projections forecast a possible [percentage]% reduction within the next [timeframe], depending on market dynamics.
- Patent expiry will be a major inflection point impacting pricing and market share.
- Strategic positioning before patent expiration is critical for maintaining profitability.
FAQs
Q1: When is patent expiration for NDC 46122-0783?
A1: The patent expires in [year], opening the market to biosimilars and generic alternatives.
Q2: What are the main competitors to this drug?
A2: Primary competitors include [list major products or biosimilars], which account for [percentage]% of market share.
Q3: How does insurance coverage affect the drug’s pricing?
A3: Reimbursement rates and formulary inclusion influence net prices, with higher coverage generally reducing patient out-of-pocket costs.
Q4: What impact will biosimilar entry have on prices?
A4: Biosimilar entry is expected to lower list prices by [estimated]%, with actual discounts varying based on negotiated contracts.
Q5: Are there upcoming clinical trials that could influence the drug’s market?
A5: Yes, ongoing trials for [new indications] could expand the market and justify price adjustments.
References
- [1] U.S. Food and Drug Administration. (2023). Approved drug products database.
- [2] IQVIA. (2023). National Prescription Audit.
- [3] SSR Health. (2022). Market trends and pricing data for biologics and biosimilars.
- [4] Medicare.gov. (2023). Formularies and reimbursement policies.
- [5] FDA. (2022). Biosimilar development and market entry guidelines.
Note: Specific drug name, manufacturer, and other detailed data should be verified with the latest official sources as needed.
